What is he best known for?
The fields of study he is best known for:
His primary areas of investigation include Cancer research, Cancer, Carcinogenesis, Pathology and Lung cancer.
His biological study spans a wide range of topics, including Transcription factor, Gene, Molecular biology, Tumor suppressor gene and Breast cancer.
His Cancer research incorporates themes from Cadherin, DNA methylation, Endometrium, Gene silencing and Epigenetics.
His DNA methylation study incorporates themes from Promoter, Methylation and Transplantation.
Edward Gabrielson interconnects Regulation of gene expression, Chromosome and Loss of heterozygosity in the investigation of issues within Carcinogenesis.
The study incorporates disciplines such as Immunohistochemistry, Carcinoma and Lung in addition to Lung cancer.
His most cited work include:
- Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network (2762 citations)
- 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. (1774 citations)
- Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors (975 citations)
What are the main themes of his work throughout his whole career to date?
Edward Gabrielson focuses on Cancer research, Pathology, Breast cancer, Lung cancer and Cancer.
His Cancer research research is multidisciplinary, incorporating elements of DNA methylation, Carcinogenesis, Tumor suppressor gene, Gene and Cancer cell.
His studies deal with areas such as Promoter and Epigenetics as well as DNA methylation.
His work in Gene addresses issues such as Molecular biology, which are connected to fields such as Biochemistry.
Edward Gabrielson has included themes like Ductal carcinoma, Lung and Adenocarcinoma in his Pathology study.
His Breast cancer research is multidisciplinary, relying on both Biomarker, Methylation and Oncology.
He most often published in these fields:
- Cancer research (36.95%)
- Pathology (26.10%)
- Breast cancer (25.30%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (22.49%)
- Cancer research (36.95%)
- Lung cancer (23.29%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Cancer research, Lung cancer, Oncology and Cancer.
His work in the fields of Internal medicine, such as Clinical trial, Immunohistochemistry and Chemotherapy, intersects with other areas such as Carboplatin.
His research in Cancer research intersects with topics in Carcinogenesis, Cancer cell, Peripheral, KRAS and T cell repertoire.
The various areas that Edward Gabrielson examines in his Lung cancer study include Major Pathologic Response, Adenocarcinoma, Blockade and Immunotherapy.
His Oncology study also includes fields such as
- Breast cancer that intertwine with fields like Methylation,
- Cohort that connect with fields like DNA methylation and Receiver operating characteristic,
- Nivolumab together with Neoadjuvant therapy and Carcinoma,
- Univariate analysis together with Odds ratio and Paclitaxel.
Edward Gabrielson specializes in Cancer, namely Primary tumor.
Between 2017 and 2021, his most popular works were:
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer (622 citations)
- Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells. (97 citations)
- Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) (94 citations)
In his most recent research, the most cited papers focused on:
The scientist’s investigation covers issues in Lung cancer, Immune checkpoint, Internal medicine, Oncology and Cancer research.
His Neoadjuvant therapy research extends to Lung cancer, which is thematically connected.
Many of his research projects under Internal medicine are closely connected to Metformin with Metformin, tying the diverse disciplines of science together.
His study in Oncology is interdisciplinary in nature, drawing from both Bevacizumab, Chemotherapy, Phases of clinical research and Major Pathologic Response.
His Cancer research research incorporates elements of Biodistribution, Atezolizumab, Cancer immunotherapy, Durvalumab and Monoclonal antibody.
The concepts of his Immunotherapy study are interwoven with issues in Survival rate, Blockade and Gene.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
